viernes, 18 de septiembre de 2020

Next Generation BLI: Gator Bio Label-Free Analysis

Medical News | Medical Articles

News Medical - Medical & Life Sciences
FacebookTwitterVimeo
 
 Antibodies 
 The latest antibodies news from News Medical 
 VHH Antibodies (Nanobodies) Advantages and LimitationsNext Generation BLI: Gator Bio Label-Free Analysis

Gator Bio offers solutions to researchers. Our next generation BLI (biolayer interferometry) technology enables the label-free measurement of biomolecules in a wide range of applications. From rapid quantitation of crude or purified samples to affinity determination of mM to pM interactions, Gator BLI can help improve your research and development.

Find Out More
 
 
  KeysightDiscover Simoa® Ultra-Sensitive Cytokine Detection to Move COVID-19
 
Recent evidence suggests cytokine imbalances may fail to clear SARS-CoV-2 infection and induce protection against reinfection. With Simoa SP-X, measuring cytokines at 10-100x lower levels enables robust quantification of healthy baselines and early rises of cytokines in order to:
  • Identify predictive biomarkers of disease severity
  • Monitor disease progression
  • Determine Th1/Th2 balance
  • Evaluate therapeutic impacts on inflammatory response
  • Quantify low abundance cytokines
  • Quantify medium- to high-abundance cytokines in low and highly diluted sample volumes
Learn More
 
 
   Using Antibodies in Immune Deficiency TreatmentUsing Antibodies in Immune Deficiency Treatment
 
Antibodies or immunoglobulins can be used in the treatment of immune deficiency disorders.
 
 Study pinpoints specific protein involved in the mass production of antibodies
 
Study pinpoints specific protein involved in the mass production of antibodiesA team of researchers has discovered how a specific protein called JAGN1 plays a crucial role in the production of antibodies.
 
 
 Candidate monoclonal antibody shows hope as COVID-19 treatment
 
Candidate monoclonal antibody shows hope as COVID-19 treatmentResearchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
 
 
 Antibody profile differentiates non-celiac gluten sensitivity from celiac disease
 
Antibody profile differentiates non-celiac gluten sensitivity from celiac diseaseA new study of the antibodies produced by people with gluten sensitivity may lead to a better way to detect the condition and treat it.
 
 
Website: www.news-medical.net
Email: info@news-medical.net
Telephone: +44 (0)161 457 7150
AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

No hay comentarios:

Publicar un comentario